<DOC>
	<DOC>NCT02791386</DOC>
	<brief_summary>The purpose of this study is to describe current rescue treatment pattern for nucleot(s)ide analogue (NA) resistance and assess the real-world treatment outcomes and health resources utilization of rescue treatments for drug resistance in a clinical cohort of Chinese patients with chronic hepatitis B (CHB).</brief_summary>
	<brief_title>Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<criteria>CHB patient with drug resistance confirmed by hepatitis B virus (HBV) gene mutation and virological breakthrough Patient receiving rescue treatments for drug resistance to previous NA therapy for CHB Patient who was regularly followed at least every 6 months for drug resistance at the tertiary liver clinic of SXH Patient with a diagnosis of hepatocellular carcinoma, decompensated cirrhosis, and/or liver transplantation prior to the development of drug resistance to NA therapy for CHB Patient with coinfection with hepatitis C virus, hepatitis D virus, and/or human immunodeficiency virus Patient with life expectancy less than 6 months after the date of the first laboratory test indicating drug resistance Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>